RxDoctor Payments Data

Peter Adesman, MD

Gastroenterology · Medford, ORNPI 1952381394

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 38.3% of the total. Reporting peaked in 2019 at $464 and has fallen 85.4% since, to $68 in 2025.

$1,222in general payments, 2019–2025

Across 51 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$468
  • Boston Scientific$343
  • Gilead$58
  • Takeda Pharmaceuticals U.S.A., Inc.$53
  • Johnson & Johnson$47
  • Braintree Laboratories, Inc.$41
  • plus $211 from 9 others

What the payments were for

  • Food & beverage$1,222100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,222 in reported general payments places this provider in the 75th percentile of 220 gastroenterology providers in Oregon.

See all gastroenterology providers in Oregon

Medicare billing

Part B allowed, 2024
$115,523
Medicare patients
557
Services billed
707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab37$325,807
Humira PenAdalimumab13$92,279
CreonLipase/Protease/Amylase17$48,384
Mesalamine40$17,123
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates231$15,447
Azathioprine63$4,592
SutabSod Sulf/Pot Chloride/Mag Sulf20$3,205
Ursodiol14$2,235
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag17$2,051
Omeprazole137$1,434
Budesonide DrBudesonide22$1,247
Famotidine80$1,060
Pantoprazole Sodium51$584
Spironolactone21$337
Sucralfate17$333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$468$48,38417 claims
Braintree Laboratories, Inc.Sutab, Suflave$41$5,25637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 220 gastroenterology providers in Oregon.

Other gastroenterology in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →